Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneratio
Not Applicable
- Conditions
- age-related macular degeneration
- Registration Number
- JPRN-UMIN000005691
- Lead Sponsor
- Department of Ophthalmology, Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
severe glaucoma, inflammation disease, diabetic retinopathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Variation on a logarithm of the minimum angle of resolution 12 months after the first intravitreal injection
- Secondary Outcome Measures
Name Time Method The rate of complication 12 months after the first intravitreal injection Variation on a central retinal thickness